21 State Attorneys General Urge Biden Administration to Ban Flavored Tobacco Products

Regulations by 2FIRSTS.ai
Jan.17.2024
21 State Attorneys General Urge Biden Administration to Ban Flavored Tobacco Products
US Attorneys General from 21 states have urged the Biden administration to swiftly implement proposed regulations banning the sale of menthol cigarettes and flavored cigars.

According to a report by the American media outlet Riverbender on January 16th, the Attorneys General from 21 US states have submitted a letter to the Biden administration, urging them to complete the review and swiftly implement proposed regulations to ban the sale of menthol cigarettes and flavored cigars.

 

The letter emphasizes the urgent need for action to remove menthol tobacco products from the market in order to safeguard public health and address the systemic and disproportionate impact of such products on minority communities and other vulnerable groups, including young people.

 

"I urge the US Food and Drug Administration (FDA) to ban menthol cigarettes and flavored cigars, as despite a decline in overall tobacco use over the past two years, flavored tobacco products continue to attract and addict new smokers, particularly among young people and minority smokers," the letter stated.

 

In their capacity as chief legal officers of various states and territories, these attorneys general have refuted baseless claims that a proposed ban on menthol cigarettes would increase illegal trade or unjustly criminalize individuals for the purchase, possession, or use of menthol cigarettes and flavored cigars. The letter asserts that the proposed regulations by the U.S. Food and Drug Administration (FDA) aim to advance health equity and protect public health.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
BAT Kenya says it has resumed sales of Velo oral nicotine pouches after receiving regulatory clarity, reinforcing its push into non-combustible products as cigarette consumption falls.The company reported a 10% drop in turnover in 2025, with revenue closing at KSh23.2 billion (about $178.64 million), largely attributed to the growing presence of illegal tobacco products.
Mar.03 by 2FIRSTS.ai
Malaysia MOH: 25,643 enforcement operations and 496,247 premises inspected nationwide as of Nov. 30
Malaysia MOH: 25,643 enforcement operations and 496,247 premises inspected nationwide as of Nov. 30
Malaysia’s Ministry of Health said it conducted 25,643 enforcement operations involving inspections of 496,247 premises nationwide as of Nov.
Jan.09 by 2FIRSTS.ai
Guam names retailers fined for selling tobacco to under-21 customers; penalties range from $2,000 to $4,000
Guam names retailers fined for selling tobacco to under-21 customers; penalties range from $2,000 to $4,000
Guam disclosed enforcement details for its 2025 tobacco retail compliance program, showing a 97.1% compliance rate among 277 inspected retailers. Nine violations were recorded, including eight underage sales cases and one signage violation, with fines ranging from $500 to $4,000.
Feb.10 by 2FIRSTS.ai
Iowa urges Eighth Circuit to allow enforcement of challenged e-cigarette directory law
Iowa urges Eighth Circuit to allow enforcement of challenged e-cigarette directory law
At the U.S. Court of Appeals for the Eighth Circuit, Iowa asked judges to allow enforcement of a challenged 2024 state law that penalizes manufacturers selling e-cigarette products not listed on a state-run directory. Products are listed only when a manufacturer or retailer meets certain premarket requirements established under the federal Food, Drug and Cosmetic Act (FDCA).
Jan.19 by 2FIRSTS.ai
California: Stiiizy hit with another lawsuit alleging high-THC vapes marketed to teens
California: Stiiizy hit with another lawsuit alleging high-THC vapes marketed to teens
A new lawsuit in California state court accuses Stiiizy Inc. of steering high-THC vape products toward teens through youth-appealing branding and weak age verification, alleging the plaintiff’s underage use was followed by cannabis-induced psychosis-related symptoms and significant personal harm.
Feb.06 by 2FIRSTS.ai